Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X 7 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5475-5479

  Subramanyam, Chakrapani ^a   Duplantier, Allen J ^a   Dombroski, Mark A ^a   Chang, Shang Poa ^a   Gabel, Christopher A ^a   Whitney Pickett, Carrie ^a   Perregaux, David G ^a   Labasi, Jeff M ^a   Yoon, Kwansik ^a   Shepard, Richard M ^a   Fisher, Michael ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Oral bioavailability; P2X 7 antagonists; Parallel medicinal chemistry; Rheumatoid arthritis; Volume of distribution

Indexed keywords

AMINE; AZAURACIL; AZINYLBENZAMIDE DERIVATIVE; AZOLYLBENZAMIDE DERIVATIVE; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PYRAZOLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SYNTHESIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ANIMALS; BENZAMIDES; CHEMISTRY TECHNIQUES, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051948910     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.06.117     Document Type: Article

References (18)

1. V. Ralevic, and G. Burnstock Pharmacol. Rev. 50 1998 413
2. R. Romagnoli, P.G. Baraldi, O. CruzLopez, C. LopezCara, D. Preti, P.A. Borea, and S. Gessi Expert Opin. Ther. Targets 12 2008 647
3. M. Solle, J. Labasi, D.G. Perregaux, E. Stam, N. Petrushova, B.H. Koller, R.J. Griffiths, and C.A. Gabel J. Biol. Chem. 276 2001 125
4. Simon D. Guile, Lilian Alcaraz, Timothy N. Birkinshaw, Keith C. Bowers, Mark R. Ebden, Mark Furber, and Michael J. Stocks J. Med. Chem. 52 2009 3123
5. A.J. Duplantier, M.A. Dombroski, C. Subramanyam, A.M. Beaulieu, S.-P. Chang, C.A. Gabel, C. Jordan, A.S. Kalgutkar, K.G. Kraus, J.M. Labasi, C.r Mussari, D.G. Perregaux, R. Shepard, T.J. Taylor, K.n A. Trevena, C. Whitney-Pickett, and K. Yoon Bioorg. Med. Chem. Lett. 21 2011 3708
6. T. Ishiyama, M. Murata, and N. Miyaura J. Org. Chem. 60 1995 7508
7. Dombroski, M. A.; Duplantier, A. J.; Subramanyam, C. WO 2,004,099,146, 2004.
8. R. Chinchilla, and C. Najera Chem. Rev. 107 2007 874
9. C.S. Lee, D.A. Allwine, M.R. Barbachyn, K.C. Grega, L.A. Dolak, C.W. Ford, R.M. Jensen, E.P. Seest, J.C. Hamel, R.D. Schaadt, D. Stapert, B.H. Yagi, G.E. Zurenko, and M.J. Genin Bioorg. Med. Chem. 9 2001 3243
10. In general these compounds were 3-5× more potent in the Yo-Pro assay than in the monocyte assay. For assay protocols, see: Duplantier, A. J.; Subramanyam, C. WO 2,003,042,191, 2003.
11. F. Lombardo, R.S. Obach, M.Y. Shalaeva, and F. Gao J. Med. Chem. 45 2002 2867
12. F. Lombardo, R.S. Obach, M.Y. Shalaeva, and F. Gao J. Med. Chem. 47 2004 1242
13. F. Lombardo, R.S. Obach, F.M. DiCapua, G. Bakken, J. Lu, D.M. Potter, F. Gao, M.D. Miller, and Y. Zhang J. Med. Chem. 49 2006 2262
14. Giuliano Berellini, Clayton Springer, Nigel J. Waters, and Franco Lombardo J. Med. Chem. 52 2009 4488
15. R. Schwesinger Chimia 39 1985 269
16. W. Xu, R. Mohan, and M.M. Morrissey Bioorg. Med. Chem. Lett. 8 1998 1089
17. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple J. Med. Chem. 45 2002 2615
18. A recent publication from Pfizer describing work completed after the work described herein disclosed a series of orally and brain available P2X7 antagonists which began with compound 27. See: X. Chen, B. Pierce, W. Naing, M.L. Grapperhaus, and D.P. Phillion Bioorg. Med. Chem. Lett. 20 2010 3107